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ute to the optimization of its dosing. The aim of this study was to 
evaluate the influence of genetic and clinical factors on TAC phar-
macokinetic variability in stable pediatric renal transplant patients.
Patients (or Materials) and Methods: This study was nested in a 
previous Prograf® to Advagraf® conversion clinical trial in pediat-
ric patients (Eudra CT: 2009-017600-89). Tacrolimus pharmacoki-
netic analysis was performed using a noncompartmental analysis. 
CYP3A5 (*3 rs776746 C> G), ABCB1 (rs1045642 C> T), POR (*28 
rs1057868 C> T and rs2868177 A> G) genotypes were determinate 
by RT-PCR using commercial Taqman® assays. The impact of indi-
vidual genetic variants on TAC AUC0–24 (adjusted by administered 
dose/kg) was evaluated and an additive unweighted genetic score was 
build. Multivariate linear regression was performed including genetic 
(genetic score), demographic, and clinical information as independ-
ent variables and TAC weight-adjusted apparent oral clearance as 
dependent variable.
Results: Twenty-one kidney transplant pediatric patients (aged 
between 4 and 17 years) on stable TAC dose were included (12 
males and 9 females). Mean (SD) body weight was 42.85 (15.42) kg. 
Subjects homozygote for CYP3A5*3 and the carriers of rs1045642, 
rs1057868, or rs2868177 have higher exposure to TAC than noncar-
riers (P < 0.05). Genetic score groups was as follows: 0 (Group 1), 1 
(Group 2), 2 (Group 3), 3 (Group 4), and 4 (Group 5) genetic variants 
in CYP3A5, ABCB1, and POR genes. There was an increase in TAC 
dose/kg adjusted AUC as the number of variants in genetic score 
increase (tendency P = 0.023) and its value is 288% higher in group 
5 compared with group 1. Genetic score, BMI, and concomitant 
deflazacort use were the only covariates retained in the multivariate 
regression model that explained 64.4% of weight-adjusted apparent 
oral clearance total variability. Genetic score, the concomitant def-
lazacort use and BMI explained 33%, 18%, and 15.4% of the total 
variability, respectively. Mean absolute error (SD) of the predicted 
weight-adjusted apparent oral clearance was of 32.82% (23.36%).
Conclusion: Genetic score composed by variants in CYP3A5, 
ABCB1, and POR genes, along BMI and concomitant deflazacort 
use, explain a clinically significant amount of the variability in oral 
clearance of tacrolimus. Larger studies are needed to evaluate the 
potential utility of these variables in predictive TAC dosing algo-
rithms.
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Introduction: The neurotransmitter serotonin (5-hydroxytryptamine; 
5-HT) 5-HT is actively cleared from synaptic spaces by SLC6A4, a 
high-affinity, Na+-, and Cl--dependent transporter localized in pre-
synaptic neuronal membranes. This brain 5-HT transporter appears 
to be a principal site of action of many antidepressant drugs including 
those of the tricyclic, SSRIs, and SSNRIs class. Many patients with 
depression are drug resistant. We hypothesized that changes in the 
transporter protein due to coding single nucleotide polymorphisms 
(SNPs) in SLC6A4 may affect transporter–drug interactions and thus 
may contribute to the resistance to antidepressant drug treatment.
Patients (or Materials) and Methods: We screened SNP databases 
(dbSNP, 1000 Genomes, ESP) for natural variants in the human 
SLC6A4 gene. We specifically focused on nonsynonymous SNPs (nsS-
NPs); that is, SNPs located in coding regions and resulting in amino 
acid variation in protein products of genes. The impact of amino acid 
substitutions caused by nsSNPs in SLC6A4 on the structure and func-
tion of SERT was investigated by using 6 different in silico prediction 
tools. Based on the crystal structure of the bacterial homologue LeuT, 
a homology model of SERT was performed, and the positions of the 
amino acid substitutions relative to the proposed substrate binding 
pocket were identified. A rating scale integrating results from in silico 
predictions and 3D modeling was applied to extract those nsSNPs 
with a potentially high impact on the structure and function of SERT. 
For future in vitro testing in transfected cells, these mutations were 
inserted in an expression vector by site-directed mutagenesis.
Results: We identified 6 nsSNPs within the SLC6A4 gene with poten-
tial effects on protein function. Two of them (H143Y and R144Q) 
reside nearby the cytoplasmatic pore between helix 2 (H2) and H3, 
which is involved in substrate binding. In both cases, the mutation 
results in a charge change and most likely in an altered pore opening 
of SERT. The third SNP (isoleucine 179 to valine) protrudes into the 
predicted binding cavity of inhibitor and substrate and therefore may 
influence substrate–transporter interaction. Another SNP causes the 
expression of a polar threonine 270 instead of a hydrophobic iso-
leucine also projecting into the cytoplasmic pore region. The P339L 
SNP is expected to destabilize H6, which is involved in substrate and 
inhibitor binding. The V488M SNP in H10 is close to the extracel-
lular pore and may affect antidepressant binding.
Conclusion: By applying a comprehensive screening approach, we 
identified 6 naturally occurring nsSNPs that are expected to affect 
substrate (5-HT) and inhibitor (antidepressant drug) binding to 
SERT. We generated transiently transfected cell lines expressing the 
6 variants. Future experiments will have to demonstrate the effects of 
these SNPs on SERT expression and transport function. Of particular 
interest is the impact of the variants on the inhibition of SERT by 
antidepressant drugs.
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Introduction: Voriconazole, an antifungal agent, is metabolized by 
CYP450 2C19 (CYP2C19). CYP2C19 activity is modulated by drug–
drug interactions (DDI) and genetic polymorphisms. We report a 
case of therapeutic use of esomeprazole that “boosted” voriconazole 
plasma concentrations in a CYP2C19 ultrarapid metabolizer HIV 
patient treated with a CYP2C19 inducer among her antiretroviral 
treatment (HAART).
Patients (or Materials) and Methods: A 35-year-old African female 
was diagnosed with AIDS in May 2012. A duodenal histoplasmosis 
and cryptococcosis infections were treated from June 2012 with a 
3-week regimen of amphotericin B–flucytosine then oral voricona-
zole 100 mg BID. HAART was initiated (emtricitabine, tenofovir, 
and raltegravir). Voriconazole doses were increased and given intra-
venously (4 mg/kg/12 h IV) as she developed a single large intrac-
ranial mass. Several voriconazole trough concentrations (C0) were 
measured below the therapeutic range (1.0–4.0 µg/mL). CYP2C19 
genotype was tested and came heterozygous for the variant allele 
CYP2C19*17, which is associated with an ultrarapid phenotype. 
A treatment with esomeprazole 40 mg BID was started and titrated 
because of severe epigastralgia (histoplasmocytosis). Subsequent 
voriconazole C0 were within the therapeutic range. After the proton 
pump inhibitor was switched to ranitidine, voriconazole C0 were 
again infratherapeutic despite an increase in voriconazole doses. 
